For Healthcare Providers

How You Can Help

You may have patients with moderately to severely active systemic lupus erythematosus (SLE). If your patients are still experiencing SLE symptoms despite stable treatment, let them know that an alternative approach is participating in clinical research.

About the
SELECT-SLE Research Study

SELECT-SLE is a Phase 3 study investigating the safety and efficacy of an investigational drug in patients with moderately to severely active SLE. The study will consist of two replicate independent, randomized, double-blinded, and placebo-controlled studies with a shared double-blind long-term extension.

The purpose of this study is to evaluate how safe and effective the investigational drug is in reducing disease activity/flares and improving the quality of life for patients living with SLE. The investigational drug is being studied in several other immune-mediated inflammatory diseases, including SLE.

Do you know any patients who meet the following criteria?

Key Inclusion Criteria

Are between 18 and 63 years old
Clinical diagnosis of SLE at least 24 weeks prior to screening as defined by the 2019 EULAR/ACR classification criteria for SLE
Have at least one of the following at screening:

ANA+ (titer ≥ 1:80)
anti-dsDNA+
anti-Smith+

hSLEDAI ≥ 6, of which ≥4 points are clinical (not based on laboratory criteria); lupus headache or organic brain syndrome do not count towards the points required for eligibility
Stable background treatment for ≥ 60 days prior to baseline (with the exception of oral corticosteroid, which must be at a stable dose for ≥14 days prior to baseline) with

antimalarial(s)
and/or prednisone (or prednisone-equivalent) ≤ 20 mg daily
and/or no more than 1 of the following: azathioprine, 6-mercaptopurine, mycophenolate mofetil, mycophenolate sodium, leflunomide, cyclosporine, tacrolimus, voclosporin, methotrexate, or mizoribine

If you have patients who may be candidates, we encourage you to share this website with them:

Lupus-SELECTSLE.com

Link Copied!

Privacy Policy Legal Notice